Isoindigo

Isoindigo

SCHEMBL12386233

O=C1Nc2ccccc2/C1=C1/C(=O)Nc2ccccc21

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 4/20 0.67
ACVR1 Q04771 2/20 0.67
MAOA P21397 1/20 0.67
MAOB P27338 1/20 0.67
PDGFRA P16234 1/20 0.67
FER P16591 1/20 0.67
LTK P29376 1/20 0.67
CDK8 P49336 1/20 0.67
DYRK1B Q9Y463 1/20 0.67
GSK3B P49841 1/20 0.52
ALDH1A1 P00352 3/20 0.52
MAPT P10636 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
NPSR1 Q6W5P4 2/20 0.52
IDO1 P14902 2/20 0.52
KDM4E B2RXH2 1/20 0.52
PKM P14618 1/20 0.52
MAPK1 P28482 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.50
NTRK1 P04629 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isoindigo SCHEMBL9899736 1.00 LRRK2 (0.67) LRRK2ACVR1MAOAMAOBPDGFRA
Isoindigo SCHEMBL29349649 1.00 LRRK2 (0.67) LRRK2ACVR1MAOAMAOBPDGFRA
Isoindigo SCHEMBL9899740 1.00 LRRK2 (0.67) LRRK2ACVR1MAOAMAOBPDGFRA
SCHEMBL2589272 0.91 LRRK2 (0.57) LRRK2ACVR1MAOAMAOBPDGFRA
SCHEMBL2589274 0.91 LRRK2 (0.57) LRRK2ACVR1MAOAMAOBPDGFRA
SCHEMBL366728 0.84
SCHEMBL2420711 0.84 LRRK2 (0.90) LRRK2ACVR1MAOAMAOBPDGFRA
Indirubin SCHEMBL9899338 0.83 MAOA (0.64) LRRK2ACVR1MAOAMAOBPDGFRA
Indirubin SCHEMBL27678 0.83 MAOA (0.64) LRRK2ACVR1MAOAMAOBPDGFRA
Indirubin SCHEMBL20535353 0.83 MAOA (0.64) LRRK2ACVR1MAOAMAOBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023155554-A1 ELECTRICALLY CONDUCTIVE POLYMER, PREPARATION METHOD THEREFOR AND LIGHT-EMITTING DIODE TCL科技集团股份有限公司 2023-08-24 WO disclosed
US-20170084839-A1 ORGANIC SEMICONDUCTING COMPOUNDS MERCK PATENT GMBH (DE) 2017-03-23 US disclosed
US-20170073499-A1 LATEX COMPRISING COLORANT AND METHODS OF MAKING THE SAME U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2017-03-16 US disclosed
US-9580578-B2 Latex comprising colorant and methods of making the same XEROX CORPORATION (US) 2017-02-28 US disclosed
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS M (US) 2016-08-25 US disclosed
US-20160185771-A1 Conjugate of Benzofuranone and Indole or Azaindole, and Preparation and Uses Thereof LUODA BIOSCIENCES, INC. (CN) 2016-06-30 US disclosed
US-20160024276-A1 LATEX COMPRISING COLORANT AND METHODS OF MAKING THE SAME U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT 2016-01-28 US disclosed
US-9213248-B2 Latex comprising colorant and methods of making the same XEROX CORPORATION (US) 2015-12-15 US disclosed
WO-2015139802-A1 ORGANIC SEMICONDUCTING COMPOUNDS MERCK PATENT GMBH (DE) 2015-09-24 WO disclosed
US-20150087687-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO BROWN DENNIS (US) 2015-03-26 US disclosed
WO-2011027077-A2 COMPOSITION COMPRISING A HYDROPHOBIC DYE, A SPECIFIC MINERAL AND/OR ORGANIC ALKALINE AGENT, A SPECIFIC COMPOUND (I) AND A SPECIFIC ORGANIC COMPOUND (II), AND USE THEREOF IN DYEING L'OREAL (FR) 2011-03-10 WO disclosed
WO-2011027076-A2 DYEING METHOD CONSISTING IN APPLYING A METALLIC SALT AND A COMPOSITION CONTAINING A HYDROPHOBIC DYE AND A SPECIFIC COMPOUND L'OREAL (FR) 2011-03-10 WO disclosed
EP-2256166-A1 Resin composition and process for producing resin molding Sony Corporation (JP) 2010-12-01 EP disclosed
US-20100144936-A1 RESIN COMPOSITION AND PROCESS FOR PRODUCING RESIN MOLDING SONY CORPORATION (JP) 2010-06-10 US disclosed
US-20100144936-A1 RESIN COMPOSITION AND PROCESS FOR PRODUCING RESIN MOLDING SONY CORPORATION (JP) 2010-06-10 US disclosed
US-20100137356-A1 AZAINDOLE-INDOLE COUPLED DERIVATIVES, PREPARATION METHODS AND USES THEREOF Cheng, Jingcai (CN) 2010-06-03 US disclosed
US-20100137356-A1 AZAINDOLE-INDOLE COUPLED DERIVATIVES, PREPARATION METHODS AND USES THEREOF Cheng, Jingcai (CN) 2010-06-03 US disclosed
US-7691928-B2 Resin composition and process for producing resin molding SONY CORPORATION (JP) 2010-04-06 US disclosed
US-7691928-B2 Resin composition and process for producing resin molding SONY CORPORATION (JP) 2010-04-06 US disclosed
EP-1218004-B1 5-METHYL INDIRUBIN FOR USE IN THE TREATMENT OF HUMAN SOLID TUMORS FIEBIG HEINZ HERBERT (DE) 2009-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170084839-A1 ORGANIC SEMICONDUCTING COMPOUNDS PPOX, OSTC, OCIAD1 LRRK2 606/4885ACVR1 1360/4885MAOA 1388/4885
US-20100137356-A1 AZAINDOLE-INDOLE COUPLED DERIVATIVES, PREPARATION METHODS AND USES THEREOF IDO1, IDO2, INMT LRRK2 1918/4885ACVR1 1658/4885MAOA 78/4885
US-20150087687-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO CYP7A1, CYP3A7, UGT2B7 LRRK2 3651/4885ACVR1 2071/4885MAOA 217/4885
US-20160243077-A1 COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO NEK9, NEK7, NEK3 LRRK2 1497/4885ACVR1 3246/4885MAOA 698/4885
US-20160185771-A1 Conjugate of Benzofuranone and Indole or Azaindole, and Preparation and Uses Thereof INMT, KMO, IDO1 LRRK2 1571/4885ACVR1 1935/4885MAOA 288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.